Product Information
ERGOMAR 2 MG TABLET SUBLINGUAL is a brand (anda) product labeled by Pangea Pharmaceuticals LLC, priced at $43.4611 per EA under NDC 81279010420. Its NADAC has been published 63 times since Jul 23, 2025.
FDA first approved this application on Feb 24, 1983.
Strength
2 mg/1
Manufacturer
Pangea Pharmaceuticals LLCNDC
81279010420
Classification
Brand (ANDA)
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERGOTAMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA087693FDA Approved
2/24/1983
On Market Since
2/3/2025
Pharmacological Classes
Price Statistics
The NADAC for ERGOMAR 2 MG TABLET SUBLINGUAL has been published 63 times since Jul 23, 2025, and over the history we have for it it has risen 3.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $43.4611 per EA |
|---|---|
| All-time high | $43.4611 (Sep 30, 2026) |
| All-time low | $41.3247 (Mar 18, 2026) |
| 52-week high | $43.4611 |
| 52-week low | $41.3247 |
| Median price | $41.8900 |
| Average price | $42.0869 |
| Largest weekly change | +3.4% (May 20, 2026) |
| Weeks tracked | 63 |
| Tracking since | Jul 23, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Ergotamine Tartrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pangea Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ergotamine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Ergotamine Derivative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERGOMAR 2 MG TABLET SUBLINGUAL?
The current National Average Drug Acquisition Cost (NADAC) for ERGOMAR 2 MG TABLET SUBLINGUAL, manufactured by Pangea Pharmaceuticals LLC, is $43.4611 per EA (NDC 81279010420), effective Sep 30, 2026.
How has the price of ERGOMAR 2 MG TABLET SUBLINGUAL changed over time?
Over the history we have for it, the NADAC for ERGOMAR 2 MG TABLET SUBLINGUAL has risen 3.8%. It has been tracked across 63 weekly CMS publications since Jul 23, 2025.
What are the highest and lowest recorded NADAC prices for ERGOMAR 2 MG TABLET SUBLINGUAL?
Since Jul 23, 2025, the NADAC for ERGOMAR 2 MG TABLET SUBLINGUAL has ranged from a low of $41.3247 (Mar 18, 2026) to a high of $43.4611 (Sep 30, 2026), with a median of $41.8900 per EA.
Are there cheaper alternatives to ERGOMAR 2 MG TABLET SUBLINGUAL?
No other NADAC-published product currently shares the active ingredient and strength of ERGOMAR 2 MG TABLET SUBLINGUAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERGOMAR 2 MG TABLET SUBLINGUAL?
ERGOMAR 2 MG TABLET SUBLINGUAL (NDC 81279010420) is labeled by Pangea Pharmaceuticals LLC, and CMS classifies it as a brand (anda) product.